MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121

NCT07768176 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-08-17

No results posted yet for this study

Summary

This is a Phase I, single-center, randomized, double-blind, placebo-controlled SAD/MAD study to evaluate safety, tolerability, and PK of Intravenously Administered PTT-121 in healthy Chinese adults.

Conditions

  • Healthy Vollunteer

Interventions

DRUG

PTT-121

PTT-121 will be administered intravenously

DRUG

PTT-121 placebo

Matching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient

Sponsors & Collaborators

  • Pyrotech Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-08-31
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07768176 on ClinicalTrials.gov